BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK halts trials;

@FierceBiotech: Will $1B cancer IP theft suit trigger tighter vigilance on researchers' work? Article  | Follow @FierceBiotech

@JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce

@FierceMedDev: DNA-sequencing penetrates Norway's healthcare system. Story | Follow @FierceMedDev

@MarkHFierce: Dudes, eat lots of walnuts and your prostate cancer risk may shrink. It worked in mice, at least... More | Follow @MarkHFierce

> When Israel's BioLineRx announced a recent deal to in-license a preclinical hepatitis C drug from Genoscience, its shares soared on speculation that the move put the company in line for a potential takeover. This morning the biotech reported that it in-licensed a second preclinical hepatitis C drug from the same company, and its shares rocketed up 34%. And that is likely to underscore feelings among many that hep C stocks are becoming notoriously volatile. Release

> Anacor shares ($ANAC) tanked this morning after it announced that its partner GlaxoSmithKline ($GSK) had suspended four studies of GSK2251052, an anti-infection treatment. The suspension was triggered by a microbiological finding in some patients. Story

> Albion Ventures and Solon Ventures are injecting $2.4 million into Xceleron, a move that will help pay for the relocation of senior analytics staff to a new facility in Germantown, MD. Some of those staffers are coming from the U.K. Release

Pharma News

@FiercePharma: Could be big if it actually ends up working. RT @FierceMedDev: Depression diagnostic passes initial trial. Story | Follow @FiercePharma

IT News

> Researchers create software-based 3-D genome map. Story

> Supercomputing supports genetic, cancer research in Arizona. Article

> Median Technologies, Sanofi sign medical imaging deal. News

> Norway's sequencing project will need major IT infrastructure. More

> Oracle announces new round of projects in IT, clinical trials. Piece

Medical Device News

> Apollo Endosurgery secures $47.6M to launch surgical tools. News

> GAO report finds some hospitals paying more for devices. Report

> Smith & Nephew, Kensey Nash impress with earnings announcements. Article

> DNA-sequencing penetrates Norway's healthcare system. Story

> ALung scores $10M in Series B. News

And Finally... Investigators concluded that mesenchymal stem cells respond to exercise, which may help point to new treatments for muscle damage. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.